|
Press Releases |
|
 |
|
Wednesday, June 10, 2020 |
|
SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress |
SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Thursday, June 4, 2020 |
|
中国抗体将于明日EULAR年会进行口头陈述 发表SM03研究成果 |
中国抗体制药有限公司(「中国抗体」或「公司」),专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司,早前宣布公司已获得欧洲抗风湿病联盟年会(「EULAR年会」)口头陈述资格,将于会上介绍关于公司旗舰产品SM03针对类风湿关节炎(RA)的II期临床研究成果。 more info >> |
|
中國抗體將於明日EULAR年會進行口頭陳述 發表SM03研究成果 |
中國抗體製藥有限公司(「中國抗體」或「公司」),專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司,早前宣佈公司已獲得歐洲抗風濕病聯盟年會(「EULAR年會」)口頭陳述資格,將於會上介紹關於公司旗艦產品SM03針對類風濕關節炎(RA)的II期臨床研究成果。 more info >> |
|
Wednesday, April 8, 2020 |
|
中國抗體獲2020年EULAR年會口述陳述資格 發表SM03研究成果 |
中國抗體製藥有限公司(「中國抗體」或「公司」),專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司,欣然宣佈公司已獲得歐洲抗風濕病聯盟年會(「EULAR年會」)口頭陳述資格,將於會上介紹關於公司旗艦產品SM03針對類風濕關節炎(「RA」)的臨床II期研究成果。 more info >> |
|
Friday, January 10, 2020 |
|
中國抗體榮獲「最受投資者歡迎新股公司」大獎 |
中國抗體製藥有限公司(「中國抗體」或「公司」,連同其附屬公司,統稱「集團」;股份代號:3681.HK),專門研究、發展、製造及商業化免疫性疾病療法且主要研製以單克隆抗體為基礎的生物藥的香港生物製藥公司,於深圳舉行的「第四屆金港股年度頒獎盛典」上榮獲「最受投資者歡迎新股公司」大獎。 more info >> |
|
SinoMab Granted the "Most Popular Newly Listed Company" Award |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Group has won the title of the "Most Popular Newly Listed Company" at the 4th Hong Kong Golden Stocks Awards held in Shenzhen. more info >> |
|
Wednesday, November 20, 2019 |
|
类风湿关节炎治疗市场蓝海潜力巨大 中国抗体公布在研药物SM03类风湿关节炎III期临床试验最新进展 |
中国抗体制药有限公司(「中国抗体」或「公司」,连同其附属公司,统称「集团」;股份代号:3681.HK),专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司,欣然宣布其旗舰在研药物SM03类风湿关节炎III期临床试验最新进展。 more info >> |
|
類風濕關節炎治療市場藍海潛力巨大 中國抗體公佈在研藥物SM03類風濕關節炎III期臨床試驗最新進展 |
中國抗體製藥有限公司(「中國抗體」或「公司」,連同其附屬公司,統稱「集團」;股份代號:3681.HK),專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司,欣然宣佈其旗艦在研藥物SM03類風濕關節炎III期臨床試驗最新進展。 more info >> |
|
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA |
SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce its latest progress of SM03 phase III clinical trial for the treatment rheumatoid arthritis. more info >> |
|
Monday, November 11, 2019 |
|
中国抗体(3681.HK):商业化进程未来可期 |
2018年港交所设立新规,允许未盈利公司在香港主板上市,由此揭开了内地生物科技公司赴港上市热潮的序幕。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Toyota Tsusho, IIJ, NEC, and NTT Com Sign Contract with Uzbektelecom for Telecommunications Infrastructure Development Project
Jan 27, 2023 15:25 JST
|
|
|
SCIB Enforces Rights to Withdraw from Project
Jan 27, 2023 13:00 HKT/SGT
|
|
|
三菱重工グループ、京都市中央卸売市場向け冷凍冷蔵倉庫をワンストップで受注
Jan 27, 2023 13:00: JST
|
|
|
三菱重工、H-IIAロケット46号機による情報収集衛星レーダ7号機の打上げ結果について
Jan 27, 2023 13:00: JST
|
|
|
マツダ、「MAZDA2」を大幅商品改良
Jan 27, 2023 11:50: JST
|
|
|
栗田工業と日立が、「環境負荷ゼロ」の循環型社会を見据えたソリューションの社会実装とエコシステムの構築に向けて本格的な協創を開始
Jan 27, 2023 11:00: JST
|
|
|
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
Jan 27, 2023 11:46 JST
|
|
|
TMC Announces Changes to Executive Structure
Jan 27, 2023 10:59 JST
|
|
|
エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」について早期アルツハイマー病に係る販売承認申請が欧州医薬品庁により受理
Jan 27, 2023 08:30: JST
|
|
|
Eccentric Engine launches Virtual Retail Cloud at NADA 2023
Jan 26, 2023 23:00 HKT/SGT
|
|
|
Palladium One Initiates 2023 Exploration Program and Expands the Tyko Nickel - Copper Project, Canada
Jan 26, 2023 20:00 HKT/SGT
|
|
|
As Mentor by eDriving Passes 3.5 Billion Miles Driven, Analysis Confirms Program's Ability to Reduce Risky Driving Behaviors
Jan 26, 2023 20:00 HKT/SGT
|
|
|
Nippon Steel, Mitsubishi Corporation and ExxonMobil to Evaluate and Establish CCS Value Chains in the Asia Pacific Region
Jan 26, 2023 19:16 JST
|
|
|
Kurita Water Industries and Hitachi Launch a Co-creation to Implement Solution in Society and Build an Ecosystem for a Sustainable Society with "Zero Environmental Impact"
Jan 26, 2023 19:02 JST
|
|
|
Four Companies Announce Joint Feasibility Study of Large-Scale and Wide-Area Carbon Capture and Storage (CCS) Value Chain Project Using Ship Transportation
Jan 26, 2023 18:28 JST
|
|
|
|
More News >> |
|
|
|
|
|